TABLE 5.

Univariate and multivariate analysis for overall survival in the resected cohort (n = 112)

	n	MST, m	Univariate	Multivariate
			P	HR	P
Age (y)
≤70	54	79	0.122		0.318
>70	58	44
Sex
Male	56	48	0.253
Female	56	79
Pretreatment size
≤30 mm	96	62	0.627
>30 mm	16	71
Tumor location
Head	65	48	0.127		0.352
Body/Tail	47	79
Pretreatment CA 19‐9
≤500 U/mL	99	71	0.726
>500 U/mL	13	48
Pretreatment DUPAN2 a
≤150 U/mL	64	59	0.645
>150 U/mL	43	71
Type of radiotherapy
IMRT	21	N.R.	0.229		0.242
Conventional	91	59
Interruption of NACRT
No interruption	89	79	0.016		0.161
With interruption	23	45
Dose reduction
Full dose	103	62	0.674
Reduction	9	N.R.
Preoperative Size
≤30 mm	100	71	0.860
>30 mm	12	N.R.
Preoperative CA 19‐9
≤37 U/mL	75	45	0.564
>37 U/mL	37	71
Preoperative DUPAN2 b
≤150 U/mL	84	79	0.584
>150 U/mL	24	71
Margin status
R0	109	71	<0.001	0.182	0.006
R1	3	14
Lymph node status
Negative	85	71	0.621
Positive	27	48
Histological response c
Grade 1, 2a, 2b	100	59	0.109		0.129
Grade 3, 4	12	N.R.
RDI of AC
≥50%	83	82	<0.001	0.294	<0.001
None or <50%	29	27

Abbreviations: AC, adjuvant chemotherapy; HR, hazard ratio; MST, median survival time; N.R., not reached; NACRT, neoadjuvant chemoradiotherapy; RDI, relative dose intensity.

^a Data of five patients were missing.

^b Data of four patients were missing.

^c EVANS classification.